Skip to content
Screener

Ginkgo Bioworks DNA Pharmaceutical and biotechnology — Concentration risk

Other product segments

Government and defense
45%+114%
Agriculture
20%-13.0%
Food and nutrition
7%+16.7%
Consumer and technology
6%+200%
Industrial and environment
2%-50.0%

Similar metrics at other companies

Centerspace logo
CSRFee Income — Concentration risk
1.4%-0.2pp
Centerspace logo
CSRRental Income — Concentration risk
98.6%+0.2pp
Maximus logo
MMSTechnology Solutions — Concentration risk
5.3%-0.6pp
Blue Owl Capital logo
OBDCInternational — Concentration risk
7.1%+0.9pp
Blue Owl Capital logo
OBDCMidwest — Concentration risk
20.5%-1.2pp
Blue Owl Capital logo
OBDCNortheast — Concentration risk
21.7%+3.8pp

Other financials

Income statement

See full
Revenue$20.2M-48.5%
Gross profit$18.4M-45.4%
Operating income-$58.5M-0.7%
Net income-$46.7M+22.5%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$172.0M-31.6%
Total debt$404.1M-5.8%
Total equity$420.3M-31.4%
Total assets$990.0M-19.6%

Cash flow

See full
Operating cash flow-$44.3M-10.0%
CapEx$2.6M+6,792%
Free cash flow-$46.9M-16.4%

Valuation

See full
Market cap$520.64M-26.0%
Enterprise value$752.73M-14.6%
P/S4.7×+1.3×

Profitability

See full
Gross margin91.8%—
Operating margin-259.9%+1,304pp
Net margin-260%+718pp
FCF margin-156.3%+38.7pp

Returns & leverage

See full
Return on equity-56.3%+23.1pp
Debt / equity1×+0.3×
Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054298
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Government and defense45%21%41%19%
Pharmaceutical and biotechnology20442938
Agriculture20231632
Food and nutrition7675
Consumer and technology6231
Industrial and environment2445
Total revenue100%100%100%100%

Item 1. Financial Statements (Unaudited)

FAQ

What is Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk?
Ginkgo Bioworks (DNA) reported pharmaceutical and biotechnology — concentration risk of 20% in Q2 2026.
How has Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk changed year-over-year?
Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk decreased by 54.5% year-over-year, from 44% to 20%.
What does pharmaceutical and biotechnology — concentration risk mean?
This metric represents the aggregate exposure or reliance on a specific set of clients or projects within the pharmaceutical and biotechnology sector. It highlights the potential impact on revenue stability if a major partner or program within this vertical were to terminate its engagement. Monitoring this risk is essential for assessing the diversification of the company's service portfolio.

Ask your AI about Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude